UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________

FORM 8-K
CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)    August 15, 2006


Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)


Washington
0-23930
91-1549568
(State or other jurisdiction
of incorporation)
(Commission File
Number)
(IRS Employer
Identification No.)


1100 Olive Way, Suite 100, Seattle, Washington
98101
(Address of principal executive offices)
(Zip Code)


Registrant's telephone number, including area code   (206) 623-7612


Not Applicable
(Former name or former address if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 
On August 15, 2006, Louis Lacasse notified Targeted Genetics of his resignation as a member of the board of directors of Targeted Genetics effective August 15, 2006. Mr. Lacasse’s decision to resign is not related to any disagreement with Targeted Genetics or its management on any matter relating to its operations, policies or practices.
 
 
Prior to his resignation, Mr. Lacasse served as the chairman of the audit committee of the board of directors and served on the Targeted Genetics board of directors since May 1998. Targeted Genetics greatly appreciates Mr. Lacasse’s service as a director and thanks him for his leadership contributions during that time.
 
 
 
2
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  Targeted Genetics Corporation
 
 		  
 		  
 
Dated: August 18, 2006  By:   /s/ David J. Poston
 
David J. Poston
  Vice President, Finance and Chief Financial Officer

 
3